These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20711886)

  • 1. How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.
    Blacher RJ; Muiruri P; Njobvu L; Mutsotso W; Potter D; Ong'ech J; Mwai P; Degroot A; Zulu I; Bolu O; Stringer J; Kiarie J; Weidle PJ
    AIDS Care; 2010 Nov; 22(11):1323-31. PubMed ID: 20711886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia.
    Krebs DW; Chi BH; Mulenga Y; Morris M; Cantrell RA; Mulenga L; Levy J; Sinkala M; Stringer JS
    AIDS Care; 2008 Mar; 20(3):311-7. PubMed ID: 18351478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
    Glass TR; De Geest S; Hirschel B; Battegay M; Furrer H; Covassini M; Vernazza PL; Bernasconi E; Rickenboch M; Weber R; Bucher HC;
    Antivir Ther; 2008; 13(1):77-85. PubMed ID: 18389901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M; Koffi CK
    AIDS; 2007 Aug; 21(13):1799-803. PubMed ID: 17690579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting.
    Fairley CK; Permana A; Read TR
    HIV Med; 2005 Sep; 6(5):366-9. PubMed ID: 16156886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.
    Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh M; Choe KW
    J Intern Med; 2007 Mar; 261(3):268-75. PubMed ID: 17305649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of short-term success of antiretroviral therapy in HIV infection.
    Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
    J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence.
    Mannheimer S; Thackeray L; Huppler Hullsiek K; Chesney M; Gardner EM; Wu AW; Telzak EE; Lawrence J; Baxter J; Friedland G;
    AIDS Care; 2008 Feb; 20(2):161-9. PubMed ID: 18293124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting antiretroviral drug adherence among HIV/AIDS adult patients attending HIV/AIDS clinic at Moi Teaching and Referral Hospital, Eldoret, Kenya.
    Talam NC; Gatongi P; Rotich J; Kimaiyo S
    East Afr J Public Health; 2008 Aug; 5(2):74-8. PubMed ID: 19024414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Simply forgot' is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence.
    Barfod TS; Sørensen HT; Nielsen H; Rodkjaer L; Obel N
    HIV Med; 2006 Jul; 7(5):285-90. PubMed ID: 16945072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia.
    Beyene KA; Gedif T; Gebre-Mariam T; Engidawork E
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1007-15. PubMed ID: 19650153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women.
    Lazo M; Gange SJ; Wilson TE; Anastos K; Ostrow DG; Witt MD; Jacobson LP
    Clin Infect Dis; 2007 Nov; 45(10):1377-85. PubMed ID: 17968839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HAART with didanosine once versus twice daily: adherence and efficacy.
    Roca B; Lapuebla C; Vidal-Tegedor B
    Int J Infect Dis; 2005 Jul; 9(4):195-200. PubMed ID: 15964537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up.
    Knobel H; Urbina O; González A; Sorlí ML; Montero M; Carmona A; Guelar A
    HIV Med; 2009 Jul; 10(6):364-9. PubMed ID: 19490179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.